Histogenics Corporation (OCGN)
Symbol Info
Listed Symbol OCGN
Name Histogenics Corporation
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $-60.00
Price Info
21 Day Moving Average $5.0203
21 Day EMA $4.554230
50 Day Moving Average $9.7847
50 Day EMA $7.923130
200 Day EMA $20.005140
200 Day Moving Average 10.168120
52 Week High $50.40
52 Week Low $1.22
52 Week Change $-95.904800
Alpha -0.049938
Beta 3.0234
Standard Deviation 0.324164
R2 0.105532
Periods 58
Share Information
10 Day Average Volume 4,875,143
20 Day Average Volume 3,057,145
30 Day Average Volume 2,084,565
50 Day Average Volume 1,298,553
Outstanding Shares 1,576,691
Float Shares 1,132,052
Percent Float 71.80%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 55
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 101,579
Institute Holdings Percent 6.600000
Institute Sold Previous 3 Months 5,256,127
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months -
Insider Holdings Percent 0.50%
Insider Sold Previous 3 Months -
Insiders Shares Owned 444,639
Price Change
7 Day Price Change $0.6200001
7 Day Percent Change 40.52%
21 Day Price Change $-7.57
21 Day Percent Change -77.88%
30 Day Price Change $-11.65
30 Day Percent Change -84.42%
Month To Date Price Change $-0.7
Month To Date Percent -24.56%
90 Day Price Change $-10.093599
90 Day Percent Change -82.44%
Quarter To Date $-0.7
Quarter To Date Percent -24.56%
180 Day Price Change $-9.49
180 Day Percent Change -81.53%
200 Day Price Change $-4.768
200 Day Percent Change -68.92%
Year To Date $-3.154
Year To Date Percent -59.46%
Profile
Description Ocugen Inc is a clinical stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases.
Details
Issue Type CS
Market Cap $3,389,886
Sec Type EQS
Auditor Grant Thornton LLP
Total Shares Outstanding 1,576,691
CEO Shankar Musunuri
Employees 49
Last Audit UE
Classification
CIK 0001372299
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 5 Great Valley Parkway
Suite 160
Malvern, PA 19355
Website https://www.ocugen.com
Facisimile
Telephone +1 484 328-4701
Email InvestorRelations@histogenics.com
Key Ratios
Profitability
EBIT Margin -
EBITDA Margin -
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $-
Revenue Per Share $-
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $1,707,569
Price To Sales -
Price To Free Cash -0.2
PE High Last 5 Years -
Price To Book 60.2
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book -0.3
Financial Strength
Total Debt To Equity -
Int Coverage -
Current Ratio 4.0
Leverage Ratio -4.9
Quick Ratio 3.5
Long Term Debt To Capital -
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -32.95
Return On Equity 18.79
Return On Capital -
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type
Your Recent History
NASDAQ
OCGN
Ocugen
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20191022 14:38:03